AMA submission to the government review of medicines scheduling policy
The AMA lodged a submission in response to a Therapeutic Goods Administration (TGA) discussion paper that proposed changes to the medicines scheduling process. The AMA highlighted concerns raised previously with the TGA about the transparency of decision-making; the lack of information about the origin and background of scheduling change proposals; and the membership of the Advisory Committee on Medicines Scheduling.
This consultation was part of a broader government review of medicines and medical devices regulation. The AMA’s other submissions to the review are provided below: